SCHEDULE 13G/A: Wellington Management Group Discloses 12.6% Stake in Celldex Therapeutics

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 12.6% of Celldex Therapeutics, Inc.'s common stock.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, filed an Amendment No. 4 to Schedule 13G.
• The group collectively beneficially owns 8,354,151 shares of Celldex Therapeutics, Inc. Common Stock.
• This ownership represents 12.6% of the total outstanding common stock of Celldex Therapeutics, Inc.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• The filing event date was March 31, 2025.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. The sentiment is neutral as it's a regulatory filing.

Positives

• The disclosure of a significant stake by a major institutional investor like Wellington Management Group can be perceived as a vote of confidence in Celldex Therapeutics.
• The filing explicitly states that the shares are held in the ordinary course of business and not for control purposes, suggesting a passive investment strategy.

Future Outlook

This document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.

Management Comments

• Taisia Lowe, Regulatory Analyst for Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a standard disclosure of significant institutional ownership, common in the financial industry, providing transparency on large investment positions in publicly traded companies. It reflects an investment firm's portfolio allocation rather than specific company performance.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.

Key Dates

Keywords

Celldex Therapeutics, Wellington Management Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, CDLX